Publication | Open Access

Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients

ThrombopoiesisThrombosisPolycythemia VeraLaboratory HematologyClone SizeMalignant Blood DisorderHematologyBlood CellPathologyPeripheral BloodHemostasisMedicineAtherosclerosis